Close Menu

NEW YORK (GenomeWeb News) – Quidel announced that for full-year 2013 it anticipates reporting $175 million in revenues.

That would represent a 12 percent bump up from $155.7 million recorded in 2012 and would beat the average analyst estimate of $174.0 million.

The firm previously announced preliminary fourth quarter 2013 revenues of $50 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.